



We're pushing
the limits of
genetic medicine

And our goal is no limits

November 2023

generation **bio**[™]

Forward Looking Statements

Any statements in this presentation about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platform, including our rapid enzymatic synthesis (RES) technology, our research and clinical development plans, and our preclinical data and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company's product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding our novel technologies, including our immune-quiet DNA; uncertainties regarding the RES manufacturing process; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the company's cash resources are sufficient to fund the company's operating expenses and capital expenditure requirements for the period anticipated; as well as the other risks and uncertainties set forth in the “Risk Factors” section of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the company's views as of the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date on which they were made.



generation **bio**TM

Company Overview

Geoff McDonough

GBIO is bringing DNA to non-viral genetic medicines



siRNA-
GalNAc




Redosable

Loss of function

Durable



mRNA-
LNP




Redosable

Gain of function

Transient



DNA-
ctLNP



Redosable

Gain of function

Durable

GBIO is bringing DNA to non-viral genetic medicines



siRNA-
GalNAc




Redosable

Loss of function

Durable



mRNA-
LNP




Redosable

Gain of function

Transient



DNA-
ctLNP



Redosable


Gain of function

Durable

POTENTIAL HAS BEEN LIMITED BY INNATE IMMUNITY TO NUCLEIC ACIDS

Immune-quiet cargo was the gating innovation for RNA...

moderna


mRNA 

Uridine chemical modifications/purity

 **Alnylam**
PHARMACEUTICALS

siRNA 

2' ribose chemical modifications



Nelson et al., Sci. Adv. 2020

... allowing RNA to use **non-selective LNP delivery**

moderna

mRNA



Uridine chemical modifications/purity

Alnylam
PHARMACEUTICALS

siRNA




2' ribose chemical modifications

LNP Dosing

1:1 liver to spleen, none left in circulation

% of LNPs dosed




DNA innate immunity had **no known solution**



DNA

IMMUNE STIMULATION

No known modifications to make
DNA immune-quiet




LNP

NON-SPECIFIC DELIVERY

Off-target delivery drives
innate immune stimulation

We began by focusing on selective delivery




LNP


NON-SPECIFIC DELIVERY

Off-target delivery drives
innate immune stimulation


The first breakthrough was our stealth LNP to avoid clearance



Bioconjugation and targeting led to the ctLNP delivery platform




Milestone achieved for selective *in vivo* delivery to T cells



Data presented at ESGCT 2023 meeting

ctLNP platform opens broad therapeutic opportunities



ctLNP

HIGHLY SELECTIVE DELIVERY

Opens new indications by
accessing unreachable
cell types & tissues



REDOSABLE



CELL-
TARGETED



MULTI-
TISSUE

We have made deep investments in our platform

425 pending applications, 58 patent families




CARGO

34 patent families



RES MANUFACTURING

5 patent families +
trade secrets



DELIVERY

19 patent families

DNA innate immunity had **no known solution**




DNA

IMMUNE STIMULATION


No known modifications to make
DNA immune quiet

RNA modification was inspiration for immune-quiet DNA



Data presented at AICHE 2023 meeting

Immune-quiet DNA avoids all known DNA immune sensors



Data presented at AICHE 2023 meeting


iqDNA platform opens unique therapeutic landscape




iqDNA

IMMUNE QUIET

Opens new indications by replacing or inserting large genes for life



DURABLE



TITRATABLE



GAIN OF
FUNCTION


GBIO has two proprietary solutions, two unique platforms



iqDNA

IMMUNE-QUIET

Immune-quiet DNA
avoids innate immunity



ctLNP

HIGHLY SELECTIVE DELIVERY

Cell-targeted delivery avoids
clearance by liver & spleen


Our platforms have differentiated clinical attributes




iqDNA

IMMUNE-QUIET

Immune-quiet DNA
avoids innate immunity




DURABLE



TITRATABLE



GAIN OF
FUNCTION



ctLNP

HIGHLY SELECTIVE DELIVERY

Cell-targeted delivery avoids
clearance by liver & spleen



REDOSABLE



CELL-
TARGETED



MULTI-
TISSUE


Our platforms open new large therapeutic opportunities



iqDNA

IMMUNE QUIET

Opens new indications by
replacing or inserting
large genes for life



ctLNP

HIGHLY SELECTIVE DELIVERY


Opens new indications by
accessing unreachable
cell types & tissues

We are developing a broad multi-tissue portfolio



iqDNA
IMMUNE-QUIET

Opens new indications by replacing or inserting large genes for life



ctLNP
HIGHLY SELECTIVE DELIVERY

Opens new indications by accessing unreachable cell types & tissues



Liver diseases



in vivo T cell tx



Other cell types



Muscle cells





CNS

Our business model creates extraordinary leverage

iqDNA
immune-quiet DNA

ctLNP
cell-targeted LNP



Rapid development of programs within tissues

Multiple first-in-class tissue franchises

Low expected cost enables global scale for millions of patients

Drug-like profile in development and launch

Redosing paradigm familiar to payors



Platform Capabilities

Matt Stanton

generation **bio**™

We have made deep investments in our platform to solve the challenges for non-viral gene therapy




CARGO

34 patent families



RES MANUFACTURING

5 patent families +
trade secrets




DELIVERY



19 patent families



We have made deep investments in our platform to solve the challenges for non-viral gene therapy




ISH data showing ceDNA uptake into liver cells (6 hrs)







We have made deep investments in our platform to solve the challenges for non-viral gene therapy



ISH data showing ceDNA uptake into liver cells (6 hrs)



ceDNA dose-dependent transduction of hepatocytes



iqDNA is a variant of ceDNA that maintains these critical features



Advantages of increased capacity of iqDNA for large constructs



1 Improved Expression

- Larger promoters/ enhancers and/or UTRs for genes such as Factor VIII (FVIII)
- Routinely >6 kb for FVIII
- Drives improved expression relative to AAV constrained constructs

2 Large transgenes

- Full length ATP7B gene for Wilson Disease as example

3 Multiple transgenes


- Single constructs that encode for both heavy and light chain for antibody secretion
- KD and replace opportunities such as alpha-1 antitrypsin (hairpin for KD of dominant negative; replace with full native alpha-1 antitrypsin)

4 Regulatable expression

- Large enhancer and promoter regions that are responsive to physiological fluctuations
 - Example is promoters that are active only in presence of high levels of TNFa



Pooled screening techniques speed the path to discovery & development




Pooled screening approaches can be used to accelerate optimization of nucleic acid cargo or LNP delivery




Pooled screening in a single animal identifies improved promoters from a complex library of 6000 variants

Schematic of mRNA barcoding method used to track promoter strength for 6000 variants



- Numerous promoter variants identified that perform better than “best-in-class” liver promoter control
- High reproducibility observed for replicate animals in study
- High performers are being recombined and screened for additional gains

Normalized mRNA levels for each promoter plotted relative to negative & positive controls




We have made deep investments in our platform to solve the challenges for non-viral gene therapy

Rapid Enzymatic Synthesis Matches Scale of Platform Potential

cGMP EFFICIENCY

Flexible, modular cGMP manufacturing at scale




500L bioreactor
ceDNA output w/
Sf9-cell production

10L
bioreactor
output w/
RES

QUALITY

Consistent purity



IEX chromatography for ceDNA drug substance

SPEED

Robust, short cycle times

28-day biologic production cycle...



shortened to...

■ 1-day enzymatic process



ENABLES


4-week research
cycle, accelerates
preclinical R&D

Enzymatic manufacturing opens up a myriad of ways to alter structure




Site specific ligation

We can conjugate molecules in a site-specific manner



Chemical modifications

Enzymatic techniques are amenable to use of non-native or native but not typically found in DNA modifications at nucleotide level



Novel structured elements

Full sequence flexibility allows for inclusion of sequences that can form structured elements that alter function

This structural and chemical flexibility led to the discovery of iqDNA

Our Process Development team uses the Ambr[®] 250 system to optimize our production processes

Ambr[®] 250 system



- Demonstrates production from small tube to stir tank reactor scale
- High throughput, automated bioreactor system for process development
- 12 fully featured single-use 250 mL bioreactors allow scientists to evaluate multi-factor optimizations in a single experiment
- **Process parameters translate directly to 2L+ reactors to be used for larger scale**



Resin screening and optimization processes to deliver a pure Drug Substance

Chromatography Resin Screening and Optimization


- Various column chemistries and resin types are screened for overall performance
- Focus on product purity, consistent recovery, and scalability
- Example chromatogram shown at right demonstrates impurity removal (peaks 1 and 2) and product elution (peak 3)
- ÄKTA™ chromatography systems used throughout development lifecycle
- **Scalable from benchtop to large scale**



We have made deep investments in our platform to solve the challenges for non-viral gene therapy


Size and polydispersity

~70-75nm; pdi <0.05
NTA sizing:





Zeta potential

Homogeneous; neutral to slight negative



Encapsulation




Example – dehydrating and solubilizing ceDNA into ethanol – pDNA conformation

Conformation of P-Form DNA

MICHEAL H. ZEHFUS and W. CURTIS JOHNSON, JR.,

Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon 97331



P-form DNA as densely packed spheroids


QUESTION

Can we dehydrate ceDNA in ethanolic LNP input stream (with lipids), favor P-form DNA in densely packed spheroids and use to create smaller, more homogeneous LNPs?




Adaptation of P-form DNA formation to LNP manufacturing process led to smaller, more homogeneous particle sizes, which leads to better expression and tolerability

Analytics of LNPs





CryoEM:



Profile in mice


- Mice dosed IV at 0.25 mg/kg
- LNP compositions identical; same ceDNA lot
- Improvement in tolerability correlates with higher liver/spleen ratio (~30:1 liver:spleen copies/dg)





Working towards more selective ligands: scFv targeting to ASGPr provides improved alternative to GalNAc


Selectivity vs. GalNAc




Ligand	hASGPR	CD301
	KD (nM)	KD (nM)
Tri-GalNAc	30.7	7.6
Tetra-GalNAc	10.3	8.2
scFv-ASGPr	17.3	No Binding

Free scFv is more selective for ASGPR than GalNAc


Conjugation to stealth LNP



Primary Hepatocyte mRNA Expression



In vivo POC



Data presented at ESGCT 2023 meeting


Three critical elements to solving the challenges for non-viral genetic medicine



CARGO



RES MANUFACTURING




DELIVERY

A multi-channel pipette is shown in the foreground, dispensing liquid into a white plate. The pipette has eight tips, each containing a small amount of liquid. The background is a blurred laboratory setting with various equipment and containers.

iqDNA

Tracy Zimmermann

generation **bio**™



iqDNA

iqDNA avoids innate immunity

opening new indications by replacing or
inserting large genes

Unlike RNA platforms, we started with no known chemistry solutions to DNA innate immunity




Uridine chemical modifications/purity




2' ribose chemical modifications

DNA INNATE IMMUNITY



Data presented at AICHE 2023 meeting

Cytokine elevation limits therapeutic index of DNA based genetic medicines



Consequences of cytokine stimulation include poor tolerability, limited dose range and limited expression

Data presented at AICHE 2023 meeting

Multiple DNA-sensing receptors reside in cytoplasm and endolysosomal compartment of cells

cGAS-STING is a main driver of DNA recognition


TLR9 also contributes to inflammation in response to DNA

Inflammasome response to DNA is independent of cGAS-STING/TLR9

Innate immune responses to DNA driven predominantly by cGAS-STING, with contributions from TLR9 & the inflammasome

cGAS-STING is a main driver of DNA recognition


Significantly reduced cytokine response to DNA in STING KO mice



Innate immune responses to DNA driven predominantly by cGAS-STING, with contributions from TLR9 & the inflammasome


cGAS-STING is a main driver of DNA recognition

Significantly reduced cytokine response to DNA in STING KO mice



TLR9 also contributes to inflammation in response to DNA

CpG methylation to prevent TLR9 activation also reduces cytokines




Data presented at AICHE 2023 meeting

Innate immune responses to DNA driven predominantly by cGAS-STING, with contributions from TLR9 & the inflammasome


cGAS-STING is a main driver of DNA recognition

Significantly reduced cytokine response to DNA in STING KO mice




TLR9 also contributes to inflammation in response to DNA

CpG methylation to prevent TLR9 activation also reduces cytokines



Inflammasome response to DNA is independent of cGAS-STING/TLR9

Elevation of IL-18 indicates Inflammasome activation



Data presented at AICHE 2023 meeting

Unique RES process builds scale and is a driver of structural DNA innovation

Global Scale

RES LARGE SCALE RES MANUFACTURING


- Cell-free ceDNA production process
- Scalable for hundreds of millions of doses

• **Driver of structural DNA innovation**

Rapid Enzymatic Synthesis Matches Scale of Platform Potential

cGMP EFFICIENCY

Flexible, modular cGMP manufacturing at scale



500L bioreactor
ceDNA output w/
Sf9-cell production


=



10L
bioreactor
output w/
RES

QUALITY

Consistent purity



IEX chromatography for ceDNA drug substance

SPEED

Robust, short cycle times

28-day biologic production cycle...



■ 1-day enzymatic process



ENABLES

4-week research cycle, accelerates preclinical R&D

We have identified a RES-enabled solution to innate immunity we call immune-quiet DNA (iqDNA)




2.0 mg/kg i.v.
injection (LNP)



CD-1
mice

6hrs

Blood for multiplex cytokine analysis



iqDNA immune profile is consistent with avoidance of cGAS-STING, TLR9 and inflammasome pathways

iqDNA profile is not limited to mice: Clear differentiation in non-human primates




1.0 mg/kg i.v. infusion (LNP)



Cynomolgus monkeys




6hrs

Blood for multi-plex cytokine analysis



All cargos have comparable tissue distribution and exposure (data not shown)

iqDNA profile is conserved across species, including human PBMCs




Data presented at AICHE 2023 meeting

Importantly, iqDNA has demonstrated robust and durable expression with reporter luciferase gene



Robust and durable expression in mice



Durability of expression confirmed out to 30 days

Data presented at AICHE 2023 meeting

Next steps are focused on therapeutic translation of iqDNA platform for *in vivo* proof of concept



Transition from
luciferase
reporter gene
to FVIII



Leverage our
portfolio of LNPs
to optimize
iqDNA delivery




Scale iqDNA
manufacturing
for continued
work in mice
and NHPs



ctLNP

Phillip Samayoa

generation bio™



ctLNP


ctLNP platform enables access to new cell types and tissues

Cell-targeted delivery avoids off-target clearance by liver and spleen

Stealth LNP profile supports targeting to cell types and tissues beyond the liver



Stealth LNP persists in circulation and avoids liver and spleen uptake



Setting the stage for cell and tissue-selective delivery




Access to extra-hepatic tissues


Data presented at ESGCT 2023 meeting

In vivo targeted delivery could transform access to cell therapies


Ex vivo cell therapy requires a highly complex, expensive and lengthy process




Our goal is to modify target cells *in vivo* using selective and re-dosable ctLNPs



Targeting platform is a modular system built on our foundational stealth LNP technology, capable of targeting a wide variety of extra-hepatic tissues



Targeting platform is a modular system built on our foundational stealth LNP technology, capable of targeting a wide variety of extra-hepatic tissues



Select Immune Cell Targeting



Oncology
Immunology
Infectious Disease




New Tissue Discovery



Heme Disorders
Genetic Myopathies
CNS Diseases

Stealth LNP controls show low/no uptake and expression in human immune cells in hPBMC mice (mRNA cargo)


Enhanced blood exposure avoids off target clearance & available for targeting



- Stealth LNP (hPBMC)
- Stealth LNP-Tras Conjugate (hPBMC)
- Non-stealth LNP (WT)




Control conjugation does not affect basal immune cell uptake




Data presented at ESGCT 2023 meeting

Stealth LNP carrying mRNA maintains prolonged PK profile and avoids clearance by liver and spleen in NHP

Enhanced blood $T_{1/2}$ with stealth LNP in NHP




Majority of drug remains in circulation, avoiding biodistribution to the liver or spleen




Data presented at ESGCT 2023 meeting

Validated bioconjugation platform to discover and characterize cell targeted LNP conjugates

Small format ligand/conjugate discovery




Single chain antibodies




Single domain antibodies

Binding affinity (octet)




Ligand Function (in vitro)

Stability (DSF)




Cell binding (Flow)



Ligand/Conjugate Activity (in vitro/vivo)

Cell Uptake & Expression (Flow)




Site-specific conjugation chemistry

Optimization Parameters


- Linker chemistry
- Linker length
- Ligand density

Conjugation Conversion (SDS-Page)



Conjugate Stability


Particle Size and Encapsulation Efficiency (DLS)




Data presented at ESGCT 2023 meeting

Stealth LNP conjugates targeting human T cells demonstrate dose dependent, receptor specific uptake *in vitro*

Efficient conjugation of protein ligands maintains LNP stability




Conjugated LNP uptake and expression is dose dependent and target specific




Validation of T cell targeted ctLNPs for analytical quality and *in vitro* uptake/expression sets stage for *in vivo* POC experiment in hPBMC mice

- ctLNP anti-huCD3 ϵ
- ctLNP anti-huY
- ctLNP anti-huX
- ctLNP anti-huHer2
(*Non-targeting Ctrl*)



24hrs

Blood and spleen flow cytometry




Data presented at ESGCT 2023 meeting

T cell targeting LNP conjugates induce uptake *and* expression of mRNA cargo *in vivo*

GFP expression in circulating T cells


(hPBMC mice; 0.5mpk; 24hrs post dose)




Similar results seen in splenic T cells

Anti-Her2-ctLNP


Non-targeting control




Anti-CD3ε-ctLNP



Anti-huY-ctLNP




Anti-huX-ctLNP




Data presented at ESGCT 2023 meeting

Off-target cell type uptake & expression remains at baseline with successful T cell engagement

GFP Expression in Circulating Myeloid cells




GFP Expression in Splenic Myeloid & B cells




T cell targeted ctLNP demonstrates selective uptake and expression across a dose range *in vivo*

Efficient T cell transduction across dose range




Minimal off target cell uptake and expression




Majority of ctLNP cargo remains in circulation, with little off-target biodistribution

High retention in circulating blood after IV administration



Ligand targeting does not drive additional off-target distribution




Next steps are focused on therapeutic translation of extra-hepatic targeting platform



Evaluate expression and PD/efficacy of therapeutic transgenes in humanized mouse models



Translate T cell targeted ctLNPs to non-human primates



Continued optimization of stealth LNPs, targeting ligands, and conjugation process

ctLNP platform poised to broadly unlock extra-hepatic delivery

Foundational proof points in place for ctLNP platform

- ✓ ctLNPs avoid clearance organs and remain available for systemic targeting
- ✓ Targeting ligands drive highly selective, dose-responsive delivery beyond the liver
- ✓ Streamlined process for ligand discovery and bioconjugation
- ✓ Compatible with DNA and RNA cargos

Positioned to bring genetic medicines to previously unreachable cell types and tissues



Access to extra-hepatic tissues



Closing

Geoff McDonough

generation bio™

We have made deep investments in our platform

425 pending applications, 58 patent families




CARGO

34 patent families



RES MANUFACTURING

5 patent families +
trade secrets



DELIVERY

19 patent families

Our platforms have differentiated clinical attributes




iqDNA

IMMUNE-QUIET

Immune-quiet DNA
avoids innate immunity




DURABLE



TITRATABLE



GAIN OF
FUNCTION



ctLNP

HIGHLY SELECTIVE DELIVERY

Cell-targeted delivery avoids
clearance by liver & spleen



REDOSABLE



CELL
TARGETED




MULTI-
TISSUE

We are developing a broad multi-tissue portfolio



iqDNA
IMMUNE-QUIET

Opens new indications by replacing or inserting large genes for life



ctLNP
HIGHLY SELECTIVE DELIVERY

Opens new indications by accessing unreachable cell types & tissues



Liver diseases



In vivo T cell tx



Other cell types



Muscle cells




CNS


Building momentum in NHP for both platforms



Scale iqDNA manufacturing for continued work in non-human primates



Translate T cell targeted ctLNPs to non-human primates





Continued optimization of stealth LNPs, targeting ligands, and conjugation process for new cells & tissues

The GBIO platform creates extraordinary leverage

iqDNA
immune-quiet DNA

ctLNP
cell-targeted LNP



Rapid development of programs within tissues

Multiple first-in-class tissue franchises

Low expected cost enables global scale for millions of patients

Drug-like profile in development and launch

Redosing paradigm familiar to payors



generation bio™

Thank you!